Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Tel Aviv University to Collaborate on microRNA Drug Delivery Tech

Premium

Rosetta Genomics said this week that it has entered a sponsored research arrangement with Tel Aviv University tech-transfer subsidiary Ramot to develop a delivery technology for microRNA mimic-based cancer therapies.

The deal calls for the partners to work together for one year and jointly own data and intellectual property resulting from the alliance. Rosetta will contribute around $69,000 to fund research at Ramot.

Although Rosetta was founded to develop both miRNA diagnostics and therapeutics, the company has largely focused on its diagnostics efforts. However, it has been working with Ramot for several years on miRNA mimics, including one based on miR-34a for cancer (GSN 8/8/2013).

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.